Literature DB >> 17142560

Effect of genetic variants of the human flavin-containing monooxygenase 3 on N- and S-oxygenation activities.

Makiko Shimizu1, Hiroshi Yano, Satomi Nagashima, Norie Murayama, Jun Zhang, John R Cashman, Hiroshi Yamazaki.   

Abstract

The decreased capacity of the flavin-containing monooxygenase 3 (FMO3) to oxygenate xenobiotics including trimethylamine is believed to contribute to metabolic disorders. The aim of this study was to functionally characterize FMO3 variants recently found in a Japanese population and compare them with selective functional activity of other FMO3 variants. Recombinant Glu158Lys and Glu158Lys-Glu308Gly FMO3 expressed in Escherichia coli membranes showed slightly decreased N-oxygenation of benzydamine and trimethylamine. Selective functional S-oxygenation of these variants by methyl p-tolyl sulfide or sulindac sulfide was comparable to that of wild-type FMO3. The Glu158Lys-Thr201Lys-Glu308Gly and Val257Met-Met260Val variants showed significantly decreased oxygenation of typical FMO3 substrates (i.e., approximately one-tenth of the V(max)/K(m) values). Val257Met FMO3 had a lower catalytic efficiency for methyl p-tolyl sulfide and sulindac sulfide S-oxygenation. However, compared with wild-type FMO3, Val257Met FMO3 showed a similar catalytic efficiency for N-oxygenation of benzydamine and trimethylamine. The catalytic efficiency for benzydamine and trimethylamine N-oxygenation by Arg205Cys FMO3 was only moderately decreased, but it possessed decreased sulindac sulfide S-oxygenation activity. Kinetic analysis showed that Arg205Cys FMO3 was inhibited by sulindac in a substrate-dependent manner, presumably because of selective interaction between the variant enzyme and the substrate. The results suggest that the effects of genetic variation of human FMO3 could operate at the functional level for N- and S-oxygenation for typical FMO3 substrates. Genetic polymorphism in the human FMO3 gene might lead to unexpected changes of catalytic efficiency for N- and S-oxygenation of xenobiotics and endogenous materials.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17142560     DOI: 10.1124/dmd.106.013094

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  13 in total

1.  Relationships between flavin-containing mono-oxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population.

Authors:  Makiko Shimizu; Charles K Allerston; Elizabeth A Shephard; Hiroshi Yamazaki; Ian R Phillips
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

2.  Flavin-containing monooxygenase-3: induction by 3-methylcholanthrene and complex regulation by xenobiotic chemicals in hepatoma cells and mouse liver.

Authors:  Trine Celius; Andrea Pansoy; Jason Matthews; Allan B Okey; Marilyn C Henderson; Sharon K Krueger; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2010-06-04       Impact factor: 4.219

3.  Population Pharmacokinetics of Sulindac and Genetic Polymorphisms of FMO3 and AOX1 in Women with Preterm Labor.

Authors:  Jin Won Sung; Hwi-Yeol Yun; Sunny Park; Young Ju Kim; Jeong Yee; Kyung Eun Lee; Byungjeong Song; Jee Eun Chung; Hye Sun Gwak
Journal:  Pharm Res       Date:  2020-01-28       Impact factor: 4.200

4.  Developmental variations in metabolic capacity of flavin-containing mono-oxygenase 3 in childhood.

Authors:  Makiko Shimizu; Travis Denton; Marie Kozono; John R Cashman; J Steven Leeder; Hiroshi Yamazaki
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

Review 5.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

6.  Inter-individual variation in flavin-containing monooxygenase 3 in livers from Japanese: correlation with hepatic transcription factors.

Authors:  Satomi Nagashima; Makiko Shimizu; Hiroshi Yano; Norie Murayama; Toshio Kumai; Shinichi Kobayashi; F Peter Guengerich; Hiroshi Yamazaki
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

7.  Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption.

Authors:  A Joseph Bloom; Sharon E Murphy; Maribel Martinez; Linda B von Weymarn; Laura J Bierut; Alison Goate
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

8.  Novel variants of the human flavin-containing monooxygenase 3 (FMO3) gene associated with trimethylaminuria.

Authors:  Meike S Motika; Jun Zhang; Xueying Zheng; Kiersten Riedler; John R Cashman
Journal:  Mol Genet Metab       Date:  2009-02-27       Impact factor: 4.797

9.  Flavin-containing monooxygenase S-oxygenation of a series of thioureas and thiones.

Authors:  Marilyn C Henderson; Lisbeth K Siddens; Sharon K Krueger; J Fred Stevens; Karen Kedzie; Wenkui K Fang; Todd Heidelbaugh; Phong Nguyen; Ken Chow; Michael Garst; Daniel Gil; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2014-04-12       Impact factor: 4.219

10.  Nicotine dependence is associated with functional variation in FMO3, an enzyme that metabolizes nicotine in the brain.

Authors:  A M Teitelbaum; S E Murphy; G Akk; T B Baker; A Germann; L B von Weymarn; L J Bierut; A Goate; E D Kharasch; A J Bloom
Journal:  Pharmacogenomics J       Date:  2017-03-14       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.